National Cancer Center

NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma

Retrieved on: 
Tuesday, June 4, 2024

National Cancer Center and PeptiDream Inc.:

Key Points: 
  • National Cancer Center and PeptiDream Inc.:
    The National Cancer Center (President: Hitoshi Nakagama) Hospital East (Director: Toshihiko Doi) and PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced the dosing of the first patient in the human imaging study of PeptiDream’s 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CAIX), for patients with clear cell renal cell carcinoma (ccRCC) conducted at the National Cancer Center Hospital East (“the clinical research”).
  • The clinical research, which was approved by the National Cancer Center Japan’s clinical review board in April 2024, is a first-in-human imaging study of 64Cu-PD-32766 conducted in collaboration with the National Cancer Center Japan and PeptiDream.
  • This study is intended to evaluate the safety, pharmacokinetics, and accumulation of 64Cu-PD-32766 in tumors using PET in patients with newly diagnosed, relapsed or suspected relapsed ccRCC.
  • To evaluate the safety, pharmacokinetics, and exposure dose of PET/CT test with 64Cu-PD-32766 in patients with newly diagnosed, relapsed or suspected to have relapsed ccRCC.

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Retrieved on: 
Monday, April 22, 2024

Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).

Key Points: 
  • Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).
  • LCINS are histologically, mutationally, and epidemiologically distinct from smoking-related lung cancers and occur almost exclusively as adenocarcinomas and most commonly in women and individuals of Asian ancestry.
  • Dr. Goto will now lead the trial in Japan, where the incidence of non-small cell lung cancer (NSCLC) in never-smokers is double or more than that of the United States.
  • In addition, LP-300 has been administered in multiple clinical trials to more than 1,000 people and has been generally well tolerated.

National Cancer Center Names Michelle Stack CEO Following Retirement of Long-Time Leader Regina English

Retrieved on: 
Wednesday, March 13, 2024

The Board of National Cancer Center is pleased to announce that Michelle Stack has joined as CEO.

Key Points: 
  • The Board of National Cancer Center is pleased to announce that Michelle Stack has joined as CEO.
  • Ms. Stack replaces long-time leader Regina English , who is now Executive Director Emerita and Board member-at-large.
  • “We are delighted to name Michelle as CEO of National Cancer Center,” said Barry Peek , President of the Board.
  • NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; The Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project, which funds research showing particular promise in the following areas: brain tumors, melanoma, DNA repair, anti-cancer therapies, gene mutations and targeted therapeutics for breast cancer.

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

Retrieved on: 
Thursday, March 28, 2024

The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.

Key Points: 
  • The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.
  • This study will be the first combination trial conducted by a Chinese biotech to combine CDK9 inhibitor and BTK inhibitor targeting DLBCL.
  • The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively.
  • Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025, Leukemia & Lymphoma, 2021
    3.

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
Tuesday, March 19, 2024

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
Monday, February 26, 2024

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
Monday, February 26, 2024

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

Retrieved on: 
Tuesday, January 9, 2024

This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.

Key Points: 
  • This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.
  • Asieris Pharmaceuticals will leverage both in-house discoveries and external partnerships to enrich its gynecological portfolio, thereby reinforcing its leadership in women's health.
  • In November 2020, the World Health Organization (WHO) released a Global Strategy to Accelerate the Elimination of Cervical Cancer.
  • To further deliver its strategic vision and commitment in the realm of women's health, Asieris Pharmaceuticals has announced the establishment of the Women's Health Business Unit.

AHN Opens New Precision Medicine and Developmental Therapeutics Cancer Clinic at AGH

Retrieved on: 
Thursday, September 7, 2023

PITTSBURGH, Sept. 7, 2023 /PRNewswire-PRWeb/ -- The Allegheny Health Network Cancer Institute (AHNCI) announced today that it has established one of the region's first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Key Points: 
  • The AHNCI's Precision Medicine and Developmental Therapeutics Clinic focuses on serving adults with metastatic solid tumors, and patients who may need second opinions or are seeking novel treatment options for rare, complex, or advanced-stage cancers.
  • The clinic is based at the AHN Cancer Institute at Allegheny General Hospital in Pittsburgh's North Side and offers both in-person and telemedicine appointments to patients.
  • Because every cancer patient has unique characteristics and preferences, a unique genetic profile, and because cancer is a dynamic, heterogeneous disease, precision therapies are considered the next frontier of cancer treatment.
  • As director of the Precision Medicine and Developmental Therapeutics Clinic, Dr. Lopez-Chavez will lead an innovative program that offers cancer patients access to clinical research trials and novel technologies aimed at maximizing cancer recovery and improving their overall well-being.

Dr. Farouk Shami Celebrates Over 35 Years of Giving Back

Retrieved on: 
Thursday, July 6, 2023

HOUSTON, Texas, July 6, 2023 /PRNewswire/ -- Chairman and Founder of one of the largest haircare companies in the world, Farouk Systems, Inc., Dr. Farouk Shami has dedicated his life to giving back. He will be honored on July 10th, 2023 as the Spirit of Life Honoree at the upcoming fundraising gala called the City of Hope's Spirit of Life Celebration. The Spirit of Life Award is presented to individuals whose professional and humanitarian accomplishments are worthy of celebration. It is the highest honor given by City of Hope, a National Cancer Institute-designated comprehensive cancer center for diabetes, cancer and other life-threatening diseases.

Key Points: 
  • HOUSTON, Texas, July 6, 2023 /PRNewswire/ -- Chairman and Founder of one of the largest haircare companies in the world, Farouk Systems, Inc., Dr. Farouk Shami has dedicated his life to giving back.
  • Dr. Farouk Shami and Farouk Systems, Inc. have donated millions of dollars and resources to support various philanthropic causes, including COVID-19 relief to health care professionals, first responders, homeless shelters, and food banks.
  • "Giving back is the art of transforming lives and creating a ripple effect of positive change in our world," said Dr. Shami.
  • For those looking to make a difference in the groundbreaking work of City of Hope, donations can be made here.